# OnCo record soraya (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/soraya/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "soraya", "NCT04296890" ;
  schema:name "SORAYA"@en ;
  schema:description "SORAYA showed that mirvetuximab soravtansine, an antibody-drug conjugate aimed at the folate receptor, shrank about a third of platinum-resistant ovarian cancers that had already been treated with bevacizumab, and earned the first approval of a biomarker-directed drug for this setting."@en ;
  schema:url <https://onco.cc/trials/soraya/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04296890> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/>, <https://onco.cc/cancers/high-grade-serous-ovarian-cancer/>, <https://onco.cc/cancers/ovarian/> ;
  onco:drugs <https://onco.cc/drugs/mirvetuximab-soravtansine/> ;
  onco:companies <https://onco.cc/companies/abbvie/> ;
  onco:people <https://onco.cc/people/ursula-matulonis/> .